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Background: Chronic ulcerative colitis (CUC) is associated with increased risk of developing colon cancer
through a dysplasia (intraepithelial neoplasia)–carcinoma sequence.
Aims: To investigate the expression of apoptosis and inflammatory related proteins in CUC.
Methods: The expression of proteins involved in apoptosis and inflammation (inducible nitric oxide
synthase (iNOS), cyclooxygenase 2 (COX-2), Bcl-xl, Fas, and active caspase 3) was investigated and
compared with that seen in sporadic colon carcinoma.
Results: COX-2 was negative in the epithelium of all samples. iNOS was clearly present in inflammatory
areas in CUC epithelium, weakly expressed in dysplasia, and absent or weakly expressed in tumour cells.
Bcl-xl was absent in CUC, increased in dysplasia, and highly expressed in most carcinomas. Fas
expression was positive in the surface epithelium of CUC, dysplasia, and most tumour cells. Activated
caspase 3 was weakly positive in all samples, indicating limited apoptosis. Compared with CUC
associated carcinoma, iNOS was consistently expressed in sporadic colon carcinoma cells, whereas Bcl-xl
was almost absent in these tumour cells and Fas was only weakly expressed. Activated caspase 3 was
present in normal mucosal samples and some tumour cells.
Conclusion: Apoptosis related proteins—particularly iNOS, Bcl-xl, and Fas—show a distinct pattern of
expression in the CUC to carcinoma sequence, which differs from that seen in sporadic carcinoma, but
bears a striking resemblance to that seen during neoplastic progression in Barrett’s oesophagus. These
results support a causal role for chronic inflammation in cancer development in CUC, and treatment of
ulcerative colitis should aim to minimise inflammation.
C
hronic ulcerative colitis (UC) is associated with an
increased risk of malignancy that develops through a
dysplasia–carcinoma sequence.1 Dysplasia (intraepithe-
lial neoplasia) is present in more than 70% of patients with
chronic UC and cancer, and it coincides with the location of
the cancer, which arises from chronically inflamed mucosa.2 3
Dysplastic areas are often difficult to recognise on endoscopy.
They may appear to be flat or only slightly raised above the
level of the mucosa. Dysplasia may also occur within or near
raised plaque-like lesions, nodules, polyps, or masses, in
which case the term dysplasia associated lesion or mass is
used. Strong support exists for a link between chronic
inflammation and the development of cancer in the gastro-
intestinal tract.4 5 During inflammation, the activation of the
transcription factor nuclear factor kB (NF-kB) induces the
expression of many genes involved in cell survival, including
antiapoptotic genes.5 6 Continuously increased expression of
antiapoptotic proteins endows cells with a survival and
proliferation advantage and may facilitate the appearance of
tumour cells. Previously, we have studied the expression of
the inflammation activated, NF-kB regulated proteins indu-
cible nitric oxide synthase (iNOS) and cyclooxygenase 2
(COX-2) in the gastritis–metaplasia–gastric cancer sequence
and in the metaplasia–dysplasia–adenocarcinoma sequence
in Barrett’s oesophagus.7 Nitric oxide, produced by iNOS, has
been shown to inhibit apoptosis by inhibiting caspase
activity, although chronic exposure to high concentrations
of nitric oxide can also promote apoptosis.8 COX-2 inhibition
prevents cell proliferation and promotes apoptosis, and is
being considered as a chemopreventive strategy in colon
cancer.9 In addition to changes in the expression of NF-kB
regulated antiapoptotic proteins, tumour cells often show
more permanent changes in the expression of other apoptosis
related proteins, such as death receptors (Fas) and Bcl-2
family members. The Bcl-2 family of proteins plays a key role
in apoptosis by determining the susceptibility of the
mitochondrial outer membrane to pore formation. Leakage
of mitochondrial proteins through these pores into the
cytoplasm constitutes a strong apoptotic signal.
‘‘Continuously increased expression of antiapoptotic
proteins endows cells with a survival and proliferation
advantage and may facilitate the appearance of tumour
cells’’
Despite knowledge about the use of different genetic
markers in detecting colitis associated neoplasia, the patho-
genesis of colon cancer in chronic UC is still poorly under-
stood, but there are indications that the pathogenesis is
different from that of sporadic colon cancer, namely: (1)
dysplasia in UC is preceded by a long history of chronic
inflammation and can be seen at sites distant from the
cancer, whereas dysplasia in sporadic colon cancer is usually
associated with a discrete polyp without inflammation. (2)
Mutations in the ras protooncogene are present in 40–60% of
sporadic colon cancers and are probably an early event; in
contrast, in cancer associated with UC, these mutations are
less frequently seen and are probably a late event.10–12 (3) Loss
of heterozygosity (LOH) of the p53 gene and src activation
occur in UC non-dysplastic epithelium, UC associated
dysplasia, and in UC associated carcinoma, whereas there is
an absence of LOH of p53 in regions with negative, indefinite,
Abbreviations: COX-2, cyclooxygenase 2; iNOS, inducible nitric oxide
synthase; LOH, loss of heterozygosity; NF-kB, nuclear factor kB; UC,
ulcerative colitis
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or low grade dysplastic histology.13 (4) LOH at the APC loci in
UC was noted in dysplasia with associated carcinoma, but
LOH of APC was not present either in cases of non-dysplastic
epithelium or in high grade dysplasia alone. Conversely, LOH
of APC was present in four of 19 colonic adenomas.14 15
The aim of our study was to determine the expression
pattern of the NF-kB regulated antiapoptotic proteins iNOS
and COX-2, the death receptor Fas, and the antiapoptotic Bcl-
2 family member Bcl-xl in the sequence chronic UC to
chronic UC associated carcinoma. Furthermore, this expres-
sion pattern was compared with that seen previously in the
sequence from Barrett’s oesophagus to Barrett’s oesophagus
associated adenocarcinoma and with that seen in sporadic
colon carcinoma.
MATERIALS AND METHODS
Patient selection and tissue collection
Tissue samples were available from five patients who
participated in an endoscopy surveillance programme
between January 1990 and December 2002 at the Erasmus
MC University Hospital, Rotterdam, the Netherlands because
of longstanding colitis and who underwent colectomy for
colitis associated carcinoma. In addition, tissue samples were
available from four patients who underwent colectomy
because of sporadic colon carcinoma. This group was
extended with 10 additional samples, stained only for Fas
and Bcl-xl. Histology was performed on samples stained with
haematoxylin and eosin, and samples were scored for the
presence and degree of inflammation and dysplasia and the
presence of adenocarcinoma. The classification of dysplasia
was performed as proposed by Riddell et al,16 and scored by
two pathologists. Low grade dysplasia was excluded from our
study.
Immunohistochemical analysis
All staining procedures were performed on 4 mm thick,
formalin fixed, dewaxed sections. Table 1 provides details
of the immunohistochemical protocols.
Immunoreactivity scores
After staining, the immunohistochemical sections were
scored by two different observers for the percentage of
positively stained epithelial cells and tumour cells. The
intensity was not scored, because of the different immuno-
staining characteristics of the antibodies. If there were
differences in interpretation, the sample was scored again
and a consensus was reached. No staining of epithelial/
tumour cells was scored as 0; 0–10% of stained epithelial/
tumour cells was scored as 1; 11–50% was scored as 2; and
51–100% was scored as 3. Active caspase 3 was scored as
positive or negative in epithelial cells and tumour cells.
RESULTS
Characteristics of patients with UC
All five patients (three male) were the subject of surveillance
colonoscopies because of longstanding colitis (mean, 15
years) and four of five were using immunosuppressives
(three cyclosporine and one methotrexate). Colectomy was
performed in all patients because of cancer at a mean age of
50 years. The mean time to develop dysplasia/adenocarci-
noma in this group was 16 years from the time of first
diagnosis of colitis. In all cases, the carcinoma was well
differentiated.
Immunohistochemical staining of UC associated
dysplasia and cancer
Tables 2 and 3 present an overview of all the immunohisto-
chemical results.
In the epithelium of chronic UC, iNOS staining was
positive in areas of inflammation and negative in areas
without inflammation (fig 1A). In dysplasia, the iNOS score
was 1 in three of five patients and 3 in two of five patients
(fig 1B). iNOS staining in tumour cells was scored 0–1
(fig 1C). COX-2 was negative in the epithelium of all samples
but clearly positive in lamina propria immune cells, which
served as an internal control. The Fas expression score was 1
in the surface epithelium of chronic UC. In dysplasia, the
mean epithelial Fas expression score was 2 (fig 1D). In four of
Table1 Immunohistochemical staining methods
Protein Antigen retrieval Primary antibody
iNOS 2615 minutes at 98 C˚ in 1mM EDTA;
pH 8.0
Mouse monoclonal at 1/100 dilution; BD-Transduction Laboratories, San Jose,
California, USA; catalogue no. 610431
COX-2 MW; 2615 minutes at 98 C˚ in 1mM EDTA;
pH 8.0
Mouse monoclonal at 1/50 dilution; BD-Transduction Laboratories; catalogue no.
610203
Fas MW; 2615 minutes at 98 C˚ in 10mM citrate;
pH 6.0
Mouse monoclonal at 1/400 dilution; Upstate Biotechnology, Lake Placid,
Massachusetts, USA; catalogue no. 05–201
Bcl-xl MW; 2615 minutes at 98 C˚ in 0.1M Tris/HCl;
pH 9.0
Mouse monoclonal at 1/100 dilution; Zymed Laboratories, South San Francisco,
California, USA; cat. no. 33–6300
Active caspase 3 MW (700 W); 168 minutes in 10mM citrate
buffer; pH 6.0
Rabbit polyclonal at 1/100 dilution; Cell Signaling Technology, Beverley,
Massachusetts, USA; catalogue no. 9661S
All sections were paraffin wax embedded.
COX-2, cyclooxygenase 2; iNOS, inducible nitric oxide synthase; MW, microwave oven.
Table 2 Immunohistochemical staining results of the
ulcerative colitis group
iNOS COX-2 Fas Bcl-xl Active caspase 3
Patient A
UC 0 0 1 0 Positive
Dysplasia 3 0 3 2 Positive
Ca T3N2M0 1 0 3 3 Positive
Patient B
UC 0 0 1 0 Positive
Dysplasia 1 0 2 2 Positive
Ca T3N1M0 1 0 3 2 Positive
Patient C
UC 0 0 1 0 Positive
Dysplasia 1 0 1 1 Positive
Ca in situ TIS 0 0 0 1 Positive
Patient D
UC 0 0 1 0 Positive
Dysplasia 1 0 3 1 Positive
Ca T1N0M0 1 0 3 3 Positive
Patient E
UC 0 0 1 0 Positive
Dysplasia 3 0 2 1 Positive
Ca T2N1M0 0 0 3 3 Positive
Immunohistochemical score: 0, 0%; 1, 0–10%; 2, 10–50%; 3, 50–100%.
Ca, carcinoma; COX-2, cyclooxygenase 2; iNOS, inducible nitric oxide
synthase; UC, ulcerative colitis.
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five cancers the tumour cells scored 3 for Fas expression
(fig 1E).
Bcl-xl was not expressed in chronic UC, but it was
expressed in dysplasia (score, 1–2) (fig 1H) and the tumour
cells of all but one cancer (score, 3) (fig 1F). Activated
caspase 3 was weakly positive in all samples, indicating only
limited ongoing apoptosis (fig 1G).
Immunohistochemical staining of sporadic colon
carcinoma
Patients were all male with a mean age of 63 years at the time
of diagnosis. All four sporadic carcinomas were well
differentiated. Table 3 shows the he TNM classification of
the tumours, together with the immunohistochemical
staining results for the tumour samples and normal mucosa
obtained from the resection material.
The iNOS staining score was 1 in all normal mucosal
samples and 1–2 in tumour cells (fig 1H). In the normal
mucosa of the resected large bowel, staining for COX-2 was
seen in some epithelial cells and lamina propria immune
cells. The COX-2 staining score ranged from 0 to 2 in tumour
cells. In normal mucosa, the Fas expression score was 1 in the
surface epithelium and some tumour cells were also positive
(score 1; fig 1I). Bcl-xl in normal mucosa samples scored 0–1
and was absent in tumour cells (score 0) (fig 1J). Activated
caspase 3 was positive in both the normal mucosal samples
and in tumour cells (fig 1K). Because of the differences in Fas
and Bcl-xl expression between the two groups, we analysed
10 additional sporadic carcinomas for Fas and Bcl-xl staining.
In normal mucosa, epithelial Fas scored 0–1, whereas the Fas
staining score in tumour cells of sporadic carcinoma was 0 in
two of 10 samples, one in six of 10 samples, and 2 in two of
10 samples. The Bcl-xl score was 0–1 in both the additional
normal mucosa samples and the sporadic colon carcinoma
cells.
DISCUSSION
In our present study, we found increased expression of iNOS
in UC associated dysplasia, whereas iNOS expression was
absent in UC associated carcinoma. In contrast, Bcl-xl
expression was absent in chronic UC, but was clearly positive
in tumour cells. This bears a striking similarity to the
expression pattern seen for antiapoptotic proteins in Barrett’s
oesophagus associated adenocarcinoma.5 In the sequence
leading to Barrett’s associated adenocarcinoma, iNOS is
expressed in the early stage of intestinal metaplasia, although
the tumour cells themselves do not express iNOS. Similarly,
the antiapoptotic Bcl-2 family member Bcl-xl was almost
absent in the early stages leading to Barrett’s associated
adenocarcinoma, but was strongly expressed in tumour cells.
Similar to the expression pattern seen in the Barrett’s
Table 3 Immunohistochemical staining results of the
sporadic colon carcinoma group
iNOS COX-2 Fas Bcl-xl Active caspase 3
Patient A
Normal mucosa 1 0 1 1 Positive
Ca, T3N1M0 2 1 1 0 Positive
Patient B
Normal mucosa 1 1 1 1 Positive
Ca, T3N0M0 2 2 1 0 Positive
Patient C
Normal mucosa 1 1 1 0 Positive
Ca, T3N0M0 3 1 1 0 Positive
Patient D
Normal mucosa 1 1 1 1 Positive
Ca, T3N2M0 1 0 1 0 Positive
Immunohistochemical score: 0, 0%; 1, 0–10%; 2, 10–50%; 3, 50–100%.
Ca, carcinoma; COX-2, cyclooxygenase 2; iNOS, inducible nitric oxide
synthase.
Figure 1 (A) Absence of inducible nitric oxide synthase (iNOS) expression in chronic ulcerative colitis. (B) iNOS expression is present in epithelial cells
in dysplasia. (C) Absence of iNOS expression in tumour cells. (D) Fas is expressed in epithelial cells in dysplasia. (E) Fas is strongly expressed in tumour
cells. (F) Bcl-xl is expressed in epithelial cells in dysplasia. (G) Bcl-xl is expressed in tumour cells. (H) Caspase 3 is activated in epithelial cells in
dysplasia. (I) iNOS is expressed in tumour cells of sporadic adenocarcinoma. (J) Fas is weakly expressed in sporadic colon carcinoma tumour cells.
(K) Absence of Bcl-xl expression in sporadic colon carcinoma cells. (L) Caspase 3 is activated in sporadic colon cancer tumour cells.
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sequence, COX-2 expression was absent from the epithelium
at all stages, except that in Barrett’s associated adenocarci-
noma COX-2 expression was seen in a few of the tumour
cells. Both chronic UC associated carcinoma and Barrett’s
associated adenocarcinoma develop from inflamed mucosa,
and it is therefore tempting to speculate that common
mechanisms, related to the continuous induction of NF-kB
regulated antiapoptotic proteins, contribute to the malignant
progression in these disorders. Therefore, a strong recom-
mendation for the prevention of cancer in chronic UC would
be to minimise inflammation in the colon of affected
patients. According to our findings, the use of COX-2
inhibitors as a chemopreventive strategy would not be
effective.
‘‘The differential expression of Fas and Bcl-xl could be
used to distinguish chronic ulcerative colitis associated
premalignant lesions from sporadic adenomas, and thus
prevent unnecessary colectomy’’
Although our study was not meant to be an exhaustive and
systematic comparison between UC associated carcinoma and
sporadic carcinoma, we did note interesting differences in the
expression of Fas and Bcl-xl between tumour cells in UC
associated carcinoma and tumour cells in sporadic carci-
noma. Fas was strongly expressed in most UC associated
dysplasia and tumour cells, whereas it was weakly expressed
in tumour cells of the sporadic carcinomas. Furthermore, Bcl-
xl was clearly expressed in chronic UC tumour cells, but
showed only weak staining in sporadic colon cancer cells.
Because high grade dysplasia is an indication for colectomy,
whereas sporadic adenomas may be removed endoscopically,
even if they occur in an area histologically involved with
colitis, the differential expression of Fas and Bcl-xl could be
used to distinguish chronic UC associated premalignant
lesions from sporadic adenomas, and thus prevent unneces-
sary colectomy. The different expression patterns of pro-
apoptotic and antiapoptotic proteins did not result in
differences in apoptosis. Activated caspase 3, used as a
marker of apoptosis, was weakly present in both chronic UC
associated colon cancer and sporadic colon cancer, and may
be the result of increased apoptosis in the presence of
increased (tumour) cell proliferation.
In conclusion, we saw a distinct pattern of expression of
apoptosis related proteins in the sequence from chronic
ulcerative colitis to carcinoma. This pattern differs from the
one seen in sporadic carcinoma and bears more resemblance
to the sequence of events seen in Barrett’s adenocarcinoma.
Our results support a causal role for chronic inflammation in
the development of cancer in chronic UC and therefore we
propose to minimise inflammation in UC.
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Take home messages
N There was a distinct pattern of expression of apoptosis
related proteins—in particular, inducible nitric oxide
synthase, Bcl-xl, and Fas—in the sequence from
chronic ulcerative colitis to carcinoma
N This pattern differs from that seen in sporadic
carcinoma and bears more resemblance to the
sequence of events seen in the development of
Barrett’s adenocarcinoma
N These results support a causal role for chronic
inflammation in the development of cancer in chronic
ulcerative colitis and we suggest that inflammation
should be minimised in this disease
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